Pharmacokinetic and pharmacodynamic analysis of amprenavir-containing combination therapy in HIV-1-infected children.

about

Pharmacokinetics and 48-week safety and antiviral activity of fosamprenavir-containing regimens in HIV-infected 2- to 18-year-old children.

P2860

Q37439512-9C78336C-2293-4577-8F2D-B3E0C6891F4A

P2860

Pharmacokinetic and pharmacodynamic analysis of amprenavir-containing combination therapy in HIV-1-infected children.

Item

http://www.wikidata.org/entity/Q45117171

description

2004 nî lūn-bûn

@nan

2004年の論文

@ja

2004年学术文章

@wuu

2004年学术文章

@zh

2004年学术文章

@zh-cn

2004年学术文章

@zh-hans

2004年学术文章

@zh-my

2004年学术文章

@zh-sg

2004年學術文章

@yue

2004年學術文章

@zh-hant

name

Pharmacokinetic and pharmacody ...... py in HIV-1-infected children.

@en

Pharmacokinetic and pharmacody ...... py in HIV-1-infected children.

@nl

type

Item

label

Pharmacokinetic and pharmacody ...... py in HIV-1-infected children.

@en

Pharmacokinetic and pharmacody ...... py in HIV-1-infected children.

@nl

prefLabel

Pharmacokinetic and pharmacody ...... py in HIV-1-infected children.

@en

Pharmacokinetic and pharmacody ...... py in HIV-1-infected children.

@nl

P1476

Pharmacokinetic and pharmacody ...... py in HIV-1-infected children.

@en

P2093

Daniel S Stein

http://www.w3.org/2001/XMLSchema#string

Mark Johnson

http://www.w3.org/2001/XMLSchema#string

Prob2004 Study Team

http://www.w3.org/2001/XMLSchema#string

Sharon Randall

http://www.w3.org/2001/XMLSchema#string

Stephane Blanche

http://www.w3.org/2001/XMLSchema#string

Yu Lou

http://www.w3.org/2001/XMLSchema#string

P2860

Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators

Quantitative relationships between zidovudine exposure and efficacy and toxicity

Pharmacologic characteristics of indinavir, didanosine, and stavudine in human immunodeficiency virus-infected children receiving combination therapy

Population pharmacokinetics and pharmacodynamic modeling of abacavir (1592U89) from a dose-ranging, double-blind, randomized monotherapy trial with human immunodeficiency virus-infected subjects.

Pharmacokinetic and pharmacodynamic study of the human immunodeficiency virus protease inhibitor amprenavir after multiple oral dosing

Understanding the dose-effect relationship: clinical application of pharmacokinetic-pharmacodynamic models.

A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team.

A short-term study of the safety, pharmacokinetics, and efficacy of ritonavir, an inhibitor of HIV-1 protease. European-Australian Collaborative Ritonavir Study Group.

The effect of high-dose saquinavir on viral load and CD4+ T-cell counts in HIV-infected patients.

Indinavir concentrations and antiviral effect.

P304

1301-1308

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1177/0091270004269561

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2004-11-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

15496648

http://www.w3.org/2001/XMLSchema#string

Pharmacokinetic and pharmacodynamic analysis of amprenavir-containing combination therapy in HIV-1-infected children.

about

P2860

P2860

Pharmacokinetic and pharmacodynamic analysis of amprenavir-containing combination therapy in HIV-1-infected children.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698